A division of Piramal Enterprises, Ltd., Piramal Imaging was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. Because of the acquisition, many key leaders joined the company, and we gained access to a pipeline of PET imaging agents.
Driven by our core values of Knowledge, Action, and Care, our employees are committed to:
- Build our global position as an innovative and leading player in molecular imaging
- Be a competent specialist and a reliable partner in research and development, supply and commercialization of molecular tracers
- Create value for patients, physicians, and payors by improving early detection and accurate characterization of diseases leading to better outcomes, improved quality of life, and reduced healthcare cost
- Create a workplace recognized for its scientific excellence, high-caliber expertise, entrepreneurial motivation and international teamwork